Compare USEG & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USEG | NEPH |
|---|---|---|
| Founded | 1966 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 37.7M |
| IPO Year | 1995 | 2004 |
| Metric | USEG | NEPH |
|---|---|---|
| Price | $1.01 | $3.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.7M | 32.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.21 | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $32,379,000.00 | $18,789,000.00 |
| Revenue This Year | $114,854.51 | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $369.50 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.66 | $2.66 |
| 52 Week High | $2.75 | $6.42 |
| Indicator | USEG | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 57.72 |
| Support Level | $0.94 | $3.64 |
| Resistance Level | $1.08 | $3.78 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 85.80 | 85.22 |
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.